Recurrent Verrucous Carcinoma of the Larynx Completed Phase 2 Trials for Bortezomib D-mannitol (DB16741)

IndicationStatusPhase
DBCOND0029506 (Recurrent Verrucous Carcinoma of the Larynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00103259Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckTreatment